La cadena de opciones muestra datos clave de las opciones de acciones de Aptiv a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Aptiv..

Aptiv (NYSE:APTV) Bolsa, Cadena de Opciones

Aptiv

Aptiv PLC signal and power solutions segment supplies components and systems that make up a vehicle's electrical system, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The operating segments are grouped on the basis of similar product, market and operating factors: Signal and Power Solutions, which includes complete electrical architecture and component products. advanced Safety and User Experience, which includes vehicle technology and services in advanced safety, user experience, and smart vehicle computing and software, as well as cloud-native software platforms, autonomous driving technologies, and DevOps tools. Eliminations and Other.

Aptiv PLC

SpringWorks Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>) shares are trading higher on Monday after the company inked a deal to be acquired by Merck &amp; Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g45031957/merck-kgaa-darmstadt-germany-to-acquire-springworks-therapeutics-to-accelerate-sustainable-growth-" rel="noreferrer noopener">for $47 per share in cash</a>.
The acquisition price translates to an equity value of around $3.9 billion and an enterprise value of $3.4 billion (3.0 billion euros), based on SpringWorks' cash position of $461.9&nbsp;million <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43843001/springworks-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-highlight" rel="noreferrer noopener">as of December 31, 2024</a>.
As per media reports in February, Merck Germany reacted to press reports and confirmed advanced discussions <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43631130/germanys-merck-in-talks-to-buy-cancer-drug-maker-springworks-therapeutics" rel="noreferrer noopener">with&nbsp;SpringWorks Therapeutics</a>.
The offer represents a 26% premium over SpringWorks' 20-day volume-weighted average share price of $37.38 as of February 7, 2025, the day before initial market rumors of a potential acquisition surfaced.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43661635/springworks-therapeutics-secures-fda-approval-for-second-cancer-drug" rel="noreferrer noopener">SpringWorks Therapeutics Secures FDA Approval For Second Cancer Drug</a>
The deal will be financed through a combination of available cash and newly issued debt.
The acquisition aligns with Merck, Darmstadt, Germany's Healthcare division strategy, as detailed during its Capital Markets Day in October 2024, which emphasizes sourcing external innovation through licensing high-quality assets at various development stages and pursuing selective acquisitions that offer early value creation.
Additionally, the move supports the company's strategic aim to expand its Healthcare presence in the United States.
The acquisition, unanimously approved by both companies' boards, is expected to close in the second half of 2025, subject to shareholder and regulatory approvals.
As of December 31, 2024, Merck Germany <a target="_blank" href="https://www.merckgroup.com/investors/reports-and-financials/earnings-materials/2024-q4/en/2024-Q4-Report-EN.pdf" rel="noreferrer noopener">had</a> cash and cash equivalents of 2.52 billion euros.
Synergies: Once completed, the acquisition is expected to immediately contribute to Merck's revenue and become accretive to<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener"> its earnings per share pre by 2027</a>.
Notably, SpringWorks' portfolio of rare tumor treatments, including a first-in-class, systemic standard-of-care therapy for adults with desmoid tumors and the only approved treatment for adults and children with symptomatic plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1), is projected to drive immediate and sustainable revenue growth for Merck KGaA, Darmstadt, Germany.
In November 2023, The FDA approved&nbsp;SpringWorks Therapeutics' Ogsiveo (nirogacestat), an oral gamma-secretase inhibitor, for adult patients with progressing desmoid tumors who&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/11/35974211/fda-approves-springworks-therapeutics-lead-therapy-as-first-for-subtype-of-soft-tissue-sarcomas" rel="noreferrer noopener">require systemic treatment</a>.
Ogsiveo is the&nbsp;<a target="_blank" href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-rare-type-non-cancerous-tumors" rel="noreferrer noopener">first&nbsp;</a>drug to be approved for the treatment of patients with desmoid tumors, a rare subtype of soft tissue sarcomas.
Ogsiveo net product revenues were $61.5 million and $172.0 million in the fourth quarter of 2024 and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43843001/springworks-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-highlight" rel="noreferrer noopener">full year 2024, respectively</a>.
Peter Guenter, member of the Executive Board and CEO of Healthcare at Merck KGaA, Darmstadt, Germany, said, "Together, Merck KGaA, Darmstadt, Germany and SpringWorks are the perfect combination to improve outcomes for patients with rare tumors and bring therapeutic innovations to more patients worldwide while building on and reinforcing the early success of SpringWorks in the United States."
Last week, SpringWorks disclosed that its marketing authorization application (MAA) for FDA-approved treatment, OGSIVEO (nirogacestat) is currently under review by the European Medicines Agency (EMA), with a decision from the Committee for Medicinal Products for Human Use (CHMP) anticipated <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g45029219/springworks-therapeutics-announces-expected-chmp-opinion-in-q2-2025-for-nirogacestat-for-the-treat" rel="noreferrer noopener">in the second quarter of 2025</a>.
Investors can gain exposure to the stock via&nbsp;iShares Genomics Immunology and Healthcare ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDNA#NYSE">IDNA</a>) and Virtus LifeSci Biotech Products ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBP#NYSE">BBP</a>).
Price Action: SWTX shares are trading higher by 3.20% at $46.15 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/45021274" target="_blank" rel="noreferrer noopener">Merck Stays Confident On M&amp;A Despite Market Uncertainty: Analyst</a></li>
</ul>
Photo via Shutterstock

Earnings

Equities

Mid Cap

News

Guidance

Movers

IDNA

SWTX

Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion

Keefe, Bruyette &amp; Woods analyst Catherine Mealor maintains Stellar Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEL#NYSE">STEL</a>) with a Market Perform and lowers the price target from $31 to $29.

Price Target

Analyst Ratings

STEL

Keefe, Bruyette & Woods Maintains Market Perform on Stellar Bancorp, Lowers Price Target to $29

Saia Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAI#NASDAQ">SAI</a>) reported results that "shocked even the bears," with significantly worse-than-expected yields, according to JPMorgan.
The Saia Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58502bcfee7bf6000190795f/brian-ossenbeck">Analyst Brian Ossenbeck</a> maintained an Overweight rating, while slashing the price target from $436 to $299.
The Saia Thesis: Faced with pricing pressure due to intensifying competition, the higher weight per shipment did little to support margins and adversely impacted headline revenue," Ossenbeck said in the note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Contract renewals decelerated, with "customers shifting to other options," the analysts stated. Peers like TFI International rebuilt its network with small and medium businesses or scaled into larger network from scratch, like Knight-Swift Transportation Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>), he added.
Rival XPO Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>) may announce its second-quarter guidance closer to consensus expectations, given the "combination of self-help initiatives in cost savings and less net new door capacity additions compared to Saia," Ossenbeck further wrote.
SAI Price Action: Shares of Saia had declined by 2.91% to $238.47 at the time of publication on Monday.
Read More: • <a href="https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=newssearch&amp;cd=&amp;cad=rja&amp;uact=8&amp;ved=2ahUKEwj2hvfI_fqMAxXER2wGHWLEOIsQxfQBKAB6BAgJEAE&amp;url=https%3A%2F%2Fwww.benzinga.com%2Fnews%2Fearnings%2F25%2F04%2F44937938%2Fcapital-one-reports-mixed-q1-results-eps-beat-revenue-misses&amp;usg=AOvVaw3g8PTc3dpKR3V3BTnwdyaP&amp;opi=89978449">J.B. Hunt Transport Overcorrects Into a Buying Opportunity</a>
Photo: Shutterstock

Analyst Color

Earnings Misses

Reiteration

Saia's Q1 'Shocked Even The Bears': Analyst Slashes Price Target, Compares Fundamentals With Peers

Keefe, Bruyette &amp; Woods analyst Michael Perito maintains S&amp;T Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STBA#NASDAQ">STBA</a>) with a Market Perform and lowers the price target from $44 to $43.

STBA

Keefe, Bruyette & Woods Maintains Market Perform on S&T Bancorp, Lowers Price Target to $43

RBC Capital analyst Victoria McCulloch reiterates TechnipFMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTI#NYSE">FTI</a>) with a Outperform and maintains $37 price target.

RBC Capital Reiterates Outperform on TechnipFMC, Maintains $37 Price Target

Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) has outperformed the market over the past 15 years by 1.47% on an annualized basis producing an average annual return of 12.27%. Currently, Union Pacific has a market capitalization of $127.24 billion. 
Buying $100 In UNP: If an investor had bought $100 of UNP stock 15 years ago, it would be worth $550.77 today based on a price of $212.96 for UNP at the time of writing.
<h3>Union Pacific's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745856912_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

Keefe, Bruyette &amp; Woods analyst Thomas McJoynt-Griffith maintains RE/MAX Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMAX#NYSE">RMAX</a>) with a Market Perform and lowers the price target from $10 to $9.

RMAX

Keefe, Bruyette & Woods Maintains Market Perform on RE/MAX Holdings, Lowers Price Target to $9

CrowdStrike Holdings, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) on Monday showcased Charlotte AI&nbsp;Agentic Response and Charlotte AI Agentic Workflows, marking progress in <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b45032434/crowdstrike-unleashes-new-agentic-outcome-driven-ai-innovations-to-power-the-next-evolution-of-the" rel="noreferrer noopener">modern SOC operations</a>.
Combined with the previously announced&nbsp;Charlotte AI Agentic Detection Triage, Charlotte AI transcends &#8220;ask-and-respond&#8221; copilots, delivering autonomous reasoning and action on first- and third-party data.
The AI-native&nbsp;CrowdStrike Falcon platform&nbsp;is now cybersecurity&#8217;s intelligent reasoning AI platform. It draws conclusions without human prompts and takes action with bounded autonomy.
Also Read: <a href="https://www.benzinga.com/news/25/04/44837495/broadcom-unveils-ai-powered-cybersecurity-tool-to-disrupt-hackers-and-boost-resilience" target="_blank" rel="noreferrer noopener">Broadcom Unveils AI-Powered Cybersecurity Tool To Disrupt Hackers And Boost Resilience</a>
Building on Charlotte&#8217;s AI innovation, CrowdStrike extends the power of agentic AI to cybersecurity services.&nbsp;
Separately, CrowdStrike&nbsp;also introduced&nbsp;Falcon Adversary OverWatch Next-Gen SIEM to bring <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b45036404/crowdstrike-delivers-industry-first-managed-threat-hunting-across-third-party-data" rel="noreferrer noopener">managed threat hunting</a> to third-party data. This innovation extends the visibility of CrowdStrike&#8217;s elite threat hunters into unmanaged attack surfaces adversaries have long exploited. By leveraging third-party data ingested by&nbsp;Falcon Next-Gen SIEM, CrowdStrike delivers 24/7 expert detection beyond endpoints, identity, and cloud environments to stop breaches across every attack surface.
Crowdstrike stock surged 23% year-to-date. 
Joshua Brown of Ritholtz Wealth Management picked CrowdStrike <a href="https://www.benzinga.com/25/04/44759696/crowdstrike-robinhood-palo-alto-networks-and-a-health-care-stock-on-cnbcs-final-trades" target="_blank" rel="noreferrer noopener">after it announced</a> an expansion of its partnership with Alphabet Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google Cloud to enable end-to-end security for AI innovation with the company&#8217;s Falcon Cloud Security platform.
Price Action: CrowdStrike stock is down 1.8% at $417.22 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44962682/check-point-q1-earnings-revenue-beats-expectations-ceo-highlights-strong-demand-for-quantum-force-and-ai-platform" target="_blank" rel="noreferrer noopener">Check Point CEO Highlights Strong Product Demand, AI Platform Growth Amid Mixed Market Reaction</a></li>
</ul>

CRWD

GOOG

GOOGL

CrowdStrike Launches New AI Tools To Strengthen Cybersecurity, Expand Threat Detection

RBC Capital analyst Ben Hendrix maintains Otis Worldwide (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OTIS#NYSE">OTIS</a>) with a Outperform and lowers the price target from $109 to $105.

OTIS

RBC Capital Maintains Outperform on Otis Worldwide, Lowers Price Target to $105

Keefe, Bruyette &amp; Woods analyst Timothy Switzer maintains Provident Finl Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFS#NYSE">PFS</a>) with a Outperform and lowers the price target from $23 to $22.

Keefe, Bruyette & Woods Maintains Outperform on Provident Finl Servs, Lowers Price Target to $22

Keefe, Bruyette &amp; Woods analyst Timothy Switzer maintains OceanFirst Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCFC#NASDAQ">OCFC</a>) with a Market Perform and lowers the price target from $21 to $20.

OCFC

Keefe, Bruyette & Woods Maintains Market Perform on OceanFirst Financial, Lowers Price Target to $20

WIIM

RVTY

RVTY stock has given up its prior gain. Revvity shares were trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 sales guidance with its midpoint above estimates.

RBC Capital analyst Ben Hendrix maintains HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) with a Outperform and lowers the price target from $384 to $376.

RBC Capital Maintains Outperform on HCA Healthcare, Lowers Price Target to $376

Keefe, Bruyette &amp; Woods analyst Wood Lay maintains Origin Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OBK#NYSE">OBK</a>) with a Outperform and lowers the price target from $44 to $41.

Keefe, Bruyette & Woods Maintains Outperform on Origin Bancorp, Lowers Price Target to $41

Plans to introduce hydrogen trucks to Southern California-based Toyota North American Parts Center fleetInvestments in hydrogen infrastructure to benefit trucking fleets and consumersNorth American debut of Toyota's more
<ul>
<li>Plans to introduce hydrogen trucks to Southern California-based Toyota North American Parts Center fleet</li>
<li>Investments in hydrogen infrastructure to benefit trucking fleets and consumers</li>
<li>North American debut of Toyota's more efficient, more powerful Gen 3 FC system</li>
</ul>
&nbsp;Toyota Motor North America (Toyota) today reaffirmed its commitment to a Hydrogen Society at the 2025 Advanced Clean Transportation Expo, introducing hydrogen-related plans, investments and debuting new fuel cell technologies and products.
At a keynote during the ACT Expo's Hydrogen Workshop, Toyota Group Vice President of Powertrain Engineering Jordan Choby announced plans to introduce hydrogen-powered fuel cell electric Class 8 heavy-duty trucks as part of an effort to reduce the number of diesel-powered tractor trailers servicing Toyota's North America Parts Center California (NAPCC). To support the new hydrogen trucks in the fleet, the company also announced plans for a new hydrogen fueling station to be built on the NAPCC campus, as well as plans to further invest and vertically integrate into the hydrogen ecosystem.
Toyota also debuted its next-generation fuel cell technology in North America, the Toyota Gen 3 FC system.
"Hydrogen as a fuel – and especially fuel cells – offer benefits that can make a positive change, and we are invested in their long-term success," Choby said. "We are investing in resources that we believe will lead to sustainable growth, both for our operations and the entire value chain in this still-evolving transportation sector."
With Class 8 heavy-duty trucks powered by fuel cells moving out of their pilot phase, Toyota will begin introducing production-level FCEV trucks to its logistics fleet, running routes from the Port of Long Beach to the NAPCC in Ontario, California, and even as far south as San Diego. The shift is part of Toyota's <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4414566-1&amp;h=1490518336&amp;u=https%3A%2F%2Fwww.toyota.com%2F2050challenge%2F&amp;a=2050+Challenge">2050 Challenge</a> goal of reducing carbon dioxide emissions from its supply chain.
"Our goals, capabilities to accomplish those goals and long-term mindset have put Toyota in a position to be a leader moving the global transportation industry forward," Choby said.
To bring its plans to life, Toyota is working with Air Liquide and Iwatani to strengthen fueling infrastructure. With Iwatani, there is an additional focus on commercial vehicles for a state-of-the-art station using new liquid hydrogen technology and SAE J2601/5-capable high-flow fueling systems. The high-flow system enables faster fueling than conventional hydrogen fueling stations, comparable in fueling time with diesel fuel pumps, and especially useful to fleet and commercial customers in helping improve operational uptime.
Toyota and Air Liquide will work together on sourcing and delivering hydrogen molecules from Air Liquide's dedicated hydrogen mobility plant in North Las Vegas, Nevada, with a focus on supplying the NAPCC station with reliable, affordable liquid hydrogen.
Toyota will also look to build relationships with other companies and organizations in the U.S. as well as those abroad.
In Japan, Toyota Motor Corporation is <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4414566-1&amp;h=4063463343&amp;u=https%3A%2F%2Fglobal.toyota%2Fen%2Fnewsroom%2Fcorporate%2F40388622.html&amp;a=collaborating+with+Chiyoda">collaborating with Chiyoda</a> on electrolysis technology, where they are combining their respective expertise in industrial products and plant engineering. Electrolyzers are devices capable of splitting water molecules into hydrogen and oxygen, the process to generate hydrogen fuel. Toyota is also looking to extract hydrogen from the methane byproducts derived from animal waste, wastewater treatment plants and landfills.
"Hydrogen is another path to energy independence, security and innovation, expanding how we can move people, goods, information, energy, and society," Choby said.
Finally, Choby provided an introduction of <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4414566-1&amp;h=156868976&amp;u=https%3A%2F%2Fpressroom.toyota.com%2Ftoyota-develops-new-fuel-cell-system%2F&amp;a=Toyota%27s+new%2C+next-generation+Gen+3+FC">Toyota's new, next-generation Gen 3 FC</a> system for its North American debut at ACT Expo. The presentation on the new system outlined a preliminary arrival in the U.S. in or after 2027. The Gen 3 FC system has been designed with versatility in mind, with different sizes and power outputs for commercial, heavy trucking and passenger vehicle applications. The next-gen system is expected to be 20% more efficient and 20% more powerful than the current system.

Toyota Motor North America Reaffirms Its Commitment To A Hydrogen Society, Introduces Hydrogen-Related Plans And Investments, Debuts New Fuel Cell Technologies And Products Including North American Debut Of Its Gen 3 FC System

Keefe, Bruyette &amp; Woods analyst Wood Lay maintains First Western Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYFW#NASDAQ">MYFW</a>) with a Outperform and raises the price target from $24 to $26.

MYFW

Keefe, Bruyette & Woods Maintains Outperform on First Western Financial, Raises Price Target to $26

Macro Economic Events

Global

Economics

Watching Shares Of Companies In Spain; Reuters Reports Spanish PM Sanchez Addressed The Nation On Power Outages, Says No Conclusive Information On Causes Of Blackout; Payment Systems Are Working Normally, As Well As Digital Banking

Ant Group&#8217;s <a target="_blank" href="https://www.benzinga.com/topic/alipay" rel="noreferrer noopener">mobile payment platform</a>, Alipay, reported 100 million users for its tap-and-pay service, launched on June 7, 2024.
The service is available in over 400 mainland Chinese cities and supports over 5,000 shopping brands.
Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) introduced the cashless society to China with Alipay&#8217;s QR code and facial recognition function to facilitate payments, similar to Visa Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) and Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) Apple Pay, SCMP <a target="_blank" href="https://www.scmp.com/tech/big-tech/article/3307968/alipay-leads-chinas-payments-apps-tap-and-pay-service-amassing-100-million-users" rel="noreferrer noopener">reported</a> last Friday.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44871845/paypal-and-bill-holdings-downgraded-by-analyst-amid-rising-tariffs-and-slower-growth-expectations" rel="noreferrer noopener">PayPal, Bill Holdings Downgraded As Analyst &#8216;Loses Confidence&#8217;</a>
Alibaba and Ant Group founder Jack Ma expressed his conviction in the next two decades of Ant at the 20th anniversary of Alipay in December.
Ant Group boosted its global presence through its digital platform, Alipay+.&nbsp;
Ant&#8217;s early global strategy, <a target="_blank" href="https://www.benzinga.com/news/24/05/38641032/jack-ma-backed-ant-groups-alipay-broadens-payment-reach-across-continents-how-its-shaping-global-com" rel="noreferrer noopener">focused on Southeast Asia</a>, saw investments in Singapore&#8217;s 2C2P and South Korea&#8217;s Kakao Pay, which now facilitate their international growth.&nbsp;The company also expanded into emerging markets like Sri Lanka and Cambodia.
It established European partnerships, such as with Italy&#8217;s Tinaba and Nexi, and in the Middle East through Dubai Duty Free. They are focused on large tourism markets like Japan, Thailand, and Singapore while targeting European, Latin American, and Middle Eastern regions to continue growing their merchant coverage.
Prior reports indicated&nbsp;that Mastercard Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) would enhance its&nbsp;cross-border remittance capabilities by partnering with Alipay. Separately, Ant Group tapped Shanghai Fudan Microelectronics to develop integrated circuits for the service.
On Friday, the companies announced a new chip compatible with every smartphone and can work in extreme temperatures from minus 40 to 85 degrees Celsius. Ant Group has placed orders for over 10 million units, with commercialization by the second half of 2025.
Ant Group initiated a global recruitment plan to work on potential breakthroughs in artificial general intelligence (AGI) and next-generation fundamental models.
Ma <a target="_blank" href="https://www.benzinga.com/25/04/44745275/alibaba-bets-big-on-ai-with-new-cloud-tools-as-jack-ma-reemerges-in-company-comeback" rel="noreferrer noopener">relinquished his corporate</a> roles and maintained a low profile since Chinese regulators scrapped Ant Group&#8217;s initial public offering and initiated an antitrust crackdown on domestic giants, including Alibaba. However, he remains a shareholder.
Lately, Ma has frequently appeared at Alibaba offices as the Chinese e-commerce juggernaut eyes a turnaround and aspires to evolve into an AI powerhouse.
At Alipay&#8217;s 20th anniversary in December 2024, Ma emphasized the importance of AI. Ma also attended the symposium chaired by President Xi Jinping in Beijing.
Price Action:&nbsp;BABA stock is down 2.07% at $117.80 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/asia/25/04/45015548/baidu-goes-aggressive-chinas-in-ai-price-war-with-alibaba-deepseek" target="_blank" rel="noreferrer noopener">Baidu Goes Aggressive China&#8217;s In AI Price War With Alibaba, DeepSeek</a></li>
</ul>
Photo by Piotr Swat via Shutterstock

Asia

Fintech news covering the emerging Financial Technology services sector

Fintech

Emerging Markets

Tech

Media

AAPL

BABA

Ant Group's Alipay Hits 100 Million Users, Unveils New Chip To Power Fintech Expansion

Keefe, Bruyette &amp; Woods analyst Jade Rahmani maintains Meritage Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTH#NYSE">MTH</a>) with a Market Perform and lowers the price target from $90 to $77.

Keefe, Bruyette & Woods Maintains Market Perform on Meritage Homes, Lowers Price Target to $77

RBC Capital analyst Brad Heffern maintains Gaming and Leisure Props (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLPI#NASDAQ">GLPI</a>) with a Outperform and lowers the price target from $56 to $54.

Comments

Aptiv

Aptiv (APTV) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL